These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8062245)

  • 1. Introduction of a disulfide bond in the alpha 1 domain of the H-2Kb molecule confers immunogenicity to the transfected RMA-S tumors.
    Kesari KV; Geliebter J
    Cancer Res; 1994 Sep; 54(17):4580-5. PubMed ID: 8062245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracellular transport of class I MHC molecules in antigen processing mutant cell lines.
    Anderson KS; Alexander J; Wei M; Cresswell P
    J Immunol; 1993 Oct; 151(7):3407-19. PubMed ID: 8376783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of major histocompatibility complex class I alpha 1/alpha 2 domain polymorphism and in vivo expression pattern in tumor resistance: studies with transgenic mice and lymphoma cell transfectants.
    Höglund P; Waldenström M; Kärre K
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):175-81. PubMed ID: 8297899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of Ran/TC4 as a protein regulating T-cell costimulation.
    Nieland JD; Haks MC; Kremers BL; Leupers TJ; Bakker AQ; Offringa R; Kruisbeek AM
    Cancer Gene Ther; 1998; 5(5):259-73. PubMed ID: 9824045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cells engineered to express major histocompatibility complex class II molecules induce T helper cell-dependent responses that protect mice from normally lethal doses of unmodified tumor cells.
    Callahan GN; Leach DR
    Cancer Detect Prev; 1996; 20(3):199-206. PubMed ID: 8769713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete rejection of a T-cell lymphoma due to synergism of T-cell receptor costimulatory molecules, CD80, CD40L, and CD40.
    Ruybal P; Gravisaco MJ; Barcala V; Escalada A; Di Sciullo P; Waldner C; Mongini C
    Vaccine; 2008 Jan; 26(5):697-705. PubMed ID: 18155328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topology of T cell receptor-peptide/class I MHC interaction defined by charge reversal complementation and functional analysis.
    Chang HC; Smolyar A; Spoerl R; Witte T; Yao Y; Goyarts EC; Nathenson SG; Reinherz EL
    J Mol Biol; 1997 Aug; 271(2):278-93. PubMed ID: 9268659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
    Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
    Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
    Leong C; Marley J; Loh S; Robinson B; Garlepp M
    Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-surface expression and alloantigenic function of a human nonclassical class I molecule (HLA-E) in transgenic mice.
    Pacasova R; Martinozzi S; Boulouis HJ; Ulbrecht M; Vieville JC; Sigaux F; Weiss EH; Pla M
    J Immunol; 1999 May; 162(9):5190-6. PubMed ID: 10227992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
    Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
    Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.
    Martayan A; Sibilio L; Tremante E; Lo Monaco E; Mulder A; Fruci D; Cova A; Rivoltini L; Giacomini P
    J Immunol; 2009 Mar; 182(6):3609-17. PubMed ID: 19265139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules.
    Newberg MH; Smith DH; Haertel SB; Vining DR; Lacy E; Engelhard VH
    J Immunol; 1996 Apr; 156(7):2473-80. PubMed ID: 8786307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules.
    Liu Y; Wang H; Zhao J; Ma J; Wei L; Wu S; Xie T; Shen F; Trojan J; Habib N; Anthony DD; Wu M; Guo Y
    Cancer Gene Ther; 2000 Mar; 7(3):456-65. PubMed ID: 10766352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of co-expression costimulatory molecule CD80 on uptake of antigen peptide-MHC class I-GFP complex by specific T cells.
    Liu X; Zhang L; Zhang X; Yu H; Zhao X; Lu J; Qian G; Ge S
    Int J Oncol; 2007 Jun; 30(6):1389-96. PubMed ID: 17487359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cytoplasmic and the transmembrane domains are not sufficient for class I MHC signal transduction.
    Gur H; Geppert TD; Wacholtz MC; Lipsky PE
    Cell Immunol; 1999 Feb; 191(2):105-16. PubMed ID: 9973532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.